Serifatu Abubakar, | |
5070 Silver Hill Ct Apt T4, Forestville, MD 20747-2025 | |
(301) 736-7398 | |
Not Available |
Full Name | Serifatu Abubakar |
---|---|
Gender | Female |
Speciality | Licensed Practical Nurse |
Location | 5070 Silver Hill Ct Apt T4, Forestville, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1700076270 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | LP40625 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Serifatu Abubakar, 5070 Silver Hill Ct Apt T4, Forestville, MD 20747-2025 Ph: (301) 736-7398 | Serifatu Abubakar, 5070 Silver Hill Ct Apt T4, Forestville, MD 20747-2025 Ph: (301) 736-7398 |
News Archive
Nutrition scientists at the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University are introducing today the MyPlate for Older Adults which corresponds with MyPlate, the federal government's new food group symbol.
Scientists have studied the system that controls age-appropriate behavior and discovered a certain element of variation that may contribute to a species' survival from an evolutionary point of view.
Medtronic, Inc. today announced that a landmark publication highlighting results from the pivotal study for Medtronic Deep Brain Stimulation (DBS) Therapy for epilepsy, known as SANTEĀ® (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy), was published online today in the medical journal, Epilepsia. The SANTE study, sponsored by Medtronic, is the largest and most rigorous clinical study of DBS therapy for epilepsy in adults with medically refractory epilepsy with partial-onset seizures.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, launches the recommended public offer to acquire all the issued and outstanding shares of OctoPlus N.V., a service-based specialty pharmaceutical company, at an offer price of EUR 0.52 (cum dividend) per share.
Biocept, Inc., a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection, monitoring and treatment of cancer, announces a $15 million common stock purchase agreement with Aspire Capital Fund, LLC, a Chicago-based institutional investor.
› Verified 7 days ago